<DOC>
	<DOCNO>NCT00002017</DOCNO>
	<brief_summary>To evaluate safety immunological effect polyethylene glycolated-interleukin-2 ( PEG-IL-2 ) asymptomatic ( without symptom ) HIV-seropositive patient take zidovudine ( AZT ) . To enhance measure immune function well-tolerated dos PEG-IL-2 , immunomodulator , regimen design allow use outpatient normal daily activity ( i.e. , full-time employment , etc. ) . Recombinant IL-2 ( without PEG modification ) administer HIV-infected patient daily intradermal injection . At low dos use , non-toxic , well-tolerated , give systemic response measure natural killer cell lymphokine-activated killer cell activity , require daily administration . In current study , PEG modification IL-2 use since much long prolong half-life compare non-PEG compound , without loss functional activity .</brief_summary>
	<brief_title>Immunomodulation HIV-1 Infected Individuals With PEG-Interleukin-2</brief_title>
	<detailed_description>Recombinant IL-2 ( without PEG modification ) administer HIV-infected patient daily intradermal injection . At low dos use , non-toxic , well-tolerated , give systemic response measure natural killer cell lymphokine-activated killer cell activity , require daily administration . In current study , PEG modification IL-2 use since much long prolong half-life compare non-PEG compound , without loss functional activity . In first , dose-escalation phase study , PEG-IL-2 inject skin back either intradermal ( ID ) subcutaneous ( SC ) route , establish optimal dose ( give ID result local induration = &gt; 25 mm without significant toxicity ) . The ID SC route compare systemic effect toxicity . In second phase study , PEG-IL-2 administer 6-8 week use optimal dosage , frequency , route determine initial phase ( probably 2-3 time per week ) local systemic effect monitor . These include measure viral titer , peripheral blood mononuclear cell phenotype , CBC CD4 count , vitro cytotoxicity assay .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Necessary topical agent nystatin , clotrimazole , acyclovir . Aerosolized pentamidine Pneumocystis carinii pneumonia ( PCP ) prophylaxis . Oral antibiotic PCP prophylaxis hematologically stable = &gt; 30 day prior study entry . Necessary systemic agent treatment chronic disorder , diabetes asthma . Patients must : HIV1 seropositivity . Asymptomatic . No opportunistic infection 8 week prior study entry . Been azidothymidine ( AZT ) ( = &gt; 500 mg/day ) least 8 week prior begin interleukin2 ( IL2 ) , stable CD4 cell count . Prior Medication : Allowed : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Active , lifethreatening opportunistic infection ( OI ) bacterial , viral , fungal , protozoan pathogen . Fever = &gt; 101 F. within 10 day prior study entry . Significant central nervous system ( CNS ) disease include AIDS dementia , psychiatric disability , seizure disorder . Significant cardiac disease ( New York Heart Association Stage III IV ) . Significant pulmonary disease ( Forced Expiratory Volume &lt; 75 percent . Weight loss = &gt; 10 percent within last 3 month . Concurrent Medication : Excluded : Systemic therapy opportunistic infection ( OI ) . Patients follow exclude : Presence antibody interleukin2 ( IL2 ) . Diseases symptom list Exclusion CoExisting Conditions . Prior Medication : Excluded within 12 week prior study entry : Other immunomodulators . Corticosteroids . Other experimental therapy . Antineoplastic chemotherapy . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1991</verification_date>
	<keyword>Polyethylene Glycols</keyword>
	<keyword>Interleukin-2</keyword>
</DOC>